AstraZeneca's Breakthrough in COVID-19 Protection for High-Risk Patients

TipRanks11minutes ago

AstraZeneca's Antibody Cuts COVID-19 Risk Among Immunocompromised in Late-stage Study

AstraZeneca (AZN.L, AZN.ST) said Thursday its investigational long-acting antibody sipavibart showed a significant reduction in the incidence of symptomatic COVID‐19 among immunocompromised people dur

MT Newswires22minutes ago

JAK Inhibitor Market to Register Immense Growth by 2034, Predicts DelveInsight | Key Companies - Eli Lilly and Company, Incyte Corporation, Dompé Farmaceutici S.p.A, Sanofi, Celgene, AstraZeneca, Karyopharm Therapeutics

New York, USA, May 15, 2024 (GLOBE NEWSWIRE) -- JAK Inhibitor Market to Register Immense Growth by 2034, Predicts DelveInsight | Key Companies - Eli Lilly and Company, Incyte Corporation, Dompé Farmaceutici

GlobeNewswire12:00

AstraZeneca CEO Granted Performance-Based Shares

TipRanksMay 15 09:17

Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Elected as a New Board Member

STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer

AccesswireMay 15 03:05

Correction to AstraZeneca Adjusted EPS Flash Headline on April 25

AstraZeneca reported adjusted earnings per share of $2.06 for the first quarter of the year. "AstraZeneca PLC 1Q Adj EPS $7.00," flash headline at 0600 GMT on April 25, misstated the figure.

Dow JonesMay 15 02:55